TAB 1
	International multicenter clinical study -The use of preparations containing glycyrhizinic acid
	in dermatology practice - Survey of basic patients data - group Herpes zoster
	Num	Herpes zoster	Men	ø Age	Women	ø Age	A	B	C	D	DE	DT	PE	PT	E
	1	spray	A.T.	72	-	-	3	7	0	0	1	1	1	1	0
	2	spray	Š.L.	30	-	-	3	10	0	0	1	1	1	1	0
	3	spray	C.B.	50	-	-	4	7	0	0	1	1	1	1	0
	4	creme	P.J.	50	-	-	4	10	0	0	1	1	1	1	0
	5	creme	P.J.	62	-	-	5	10	0	0	1	1	1	1	0
	6	creme	Š.F.	79	-	-	5	12	0	0	1	1	1	1	0
	7	creme	-	-	M.K.	78	5	10	0	0	1	1	1	1	0
	8	creme	-	-	H.N.	56	4	12	0	0	1	1	1	1	0
	Summary		-	57,2	-	67	4,13	9,75	-	-	-	-	-	-	-
	Legend
	A - number of aplication/day
	B - duration of aplication/day
	C - Undesirable effects
	D - Relaps
	DE/DT - evaluation of doctor - effect/tolerance
	PE/PT- eavaluation of patient - effect/tolerance
	E - Interruption of application
	Effect					Tolerance
	1 - very good					1- very good
	2 - good					2 - good
	3 - no effect					3 - no effect
	4 - degradation					4 - exacerbation
	Graph 1
	International multicenter clinical study - The use of preparations containing glycyrhizinic acid
	in dermatology practice - Survey of basic patients data - group Herpes zoster
	Graph 2
	International multicenter clinical study - The use of preparations containing glycyrhizinic acid
	in dermatology practice - Survey of basic patients data - group Herpes zoster